EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial - Q

On Monday, the U.S.

Food and Drug Administration (FDA) approved Quantum BioPharma Ltd.'s (NASDAQ:QNTM) Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling it to advance its multiple sclerosis program into Phase 2 clinical development.

Advancing Phase 2 Clinical Trials The company is working with a clinical research organization with significant experience in neurodegenerative studies to support implementation of the planned disease-modifying Phase 2 study.

Preparations for the trial, including the selection of testing sites, have already begun.

The company intends to initiate patient enrollment and begin administering the drug as swiftly as possible.